StockPulse is a software subscription service that translates and summarizes U.S. stock filings and news into alerts. It is not an investment advisory, brokerage, or discretionary management service.

All information provided (filing summaries, price data, keywords, etc.) is processed from public sources for reference only and is not a recommendation to buy or sell any security. Investment decisions and their outcomes are the sole responsibility of the user.

노마드랩 주식회사 · 대표 황승준 · 사업자등록번호 588-81-01342

부산광역시 해운대구 센텀중앙로 55, 9층 7호(우동)

통신판매업 제2026-부산해운대-0983호 · 문의  

고객문의 070-4268-1176

App Store▶ Google Play
GuideFAQWeeklyTerms of ServicePrivacy PolicyPayment & Refund Policy

StockPulse · 스탁펄스(스톡펄스) — 미국주식 공시·뉴스 실시간 알림

© 2026 노마드랩 주식회사. All rights reserved.

StockPulseStockPulseFeedReportMacro·SectorsCommunityAlertsMy
Theme
FeedReportMacro·SectorsCommunityAlertsMy
INABIN8BIO, INC.
stockpulse.co.kr
Nasdaq
$1.05▲ 0.00%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $10.3MShares out 9.8M sh
At a glance🔒 At-a-glance is MAX onlySee plans

Chart

Filings & news by date

Hover (PC) or tap (mobile) a candle to see that day only

🔒 Members only
Live tape🔒 Live tape is MAX onlySee plans

Filings

2
  • 8.6After-hours26.08.07 05:11
    10-QEarnings#●●●#●●●

    IN8BIO, INC.Bullish

    IN8BIO는 2026년 2분기(6월 30일 마감) 기준 478만 달러의 영업손실과 987만 달러의 상반기 누적 영업손실을 기록했습니다. 2026년 6월 30일 기준 현금 보유액은 1,796만 달러로, 전년 말 2,709만 달러 대비 감소했습니다.…more

    $1.05+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    View filingShare
  • 8.6After-hours26.08.07 05:05
    8-KKey event

    IN8BIO, INC.

    IN8bio는 2026년 2분기 실적을 발표하며 480만 달러의 순손실(주당 0.25달러)을 기록했습니다. 주요 파이프라인인 DeltEx DRI의 임상 데이터가 긍정적으로 도출되었으며, 하반기 중 INB-619의 초기 생체 내 데이터 발표와 FDA 규제 경로 논의를 앞두고 있습니다.…more

    $1.05+0.00%vs prev close
    View filingShare

1 more filings

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →

News

GlobeNewswire
  • 10.6After-hours26.10.07 05:00
    #●●●

    IN8bio Grants Stock Options to New Employee

    IN8bio announced the grant of stock options for 60,000 shares to a new employee under Nasdaq listing rules. This is a standard compensation practice for talent acquisition and has no material impact on the company's valuation.…more

    $1.05+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    Read sourceShareGlobeNewswire
  • 9.22After-hours26.09.23 05:00

    ●●●●●●●● ●●●●● ●●●●●●

    IN8bio announced its participation in the upcoming Sidoti Small-Cap Virtual Conference to showcase its gamma-delta T cell platform and clinical pipeline. As this event is a standard investor presentation without new material business developments, the impact on the stock is expected to be neutral.…more

    $1.05+0.00%vs prev close
    Read sourceShareGlobeNewswire
  • 9.10Pre-market26.09.10 21:00

    ●●●●●●●● ●●●●● ●●●●●●

    Clinical-stage biopharmaceutical company IN8bio announced its participation in the H.C. Wainwright 28th Annual Global Investment Conference. This event involves a fireside chat and investor meetings, which are standard corporate activities without immediate financial impact.…more

    $1.05+0.00%vs prev close
    Read sourceShareGlobeNewswire

2 more news items

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →